Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. The company’s product line comprises GLUMETZA for the treatment of type ii diabetes; ProQuin XR for uncomplicated urinary tract infection; Gabapentin GR is in second phase third study for postherpetic neuralgia, diabetic peripheral neuropathy, and menopausal hot flashes; and Omeprazole for gastroesophageal reflux disease. It also develops other product candidates for treatment of gastroesophageal reflux disease are in preclinical studies stage. The company sells its products trough wholesalers and retail pharmacies. The company has a collaboration agreement with Supernus Pharmaceuticals, Inc. to develop a product candidate leveraging its AcuForm drug delivery technology; and Patheon, Inc. Depomed, Inc. was founded in 1995 and is headquartered in Menlo Park, California.
